Table 1. Demographic data of patients' and validation cohort.
|
Variable |
Patients' cohort (n=132) Median (range) |
Validation's cohort (n=72) Median (range) |
|---|---|---|
|
Age |
58 (19–84) |
60 (36–76) |
| Number of cases | Number of cases | |
|
Gender | ||
| Male | 80 | 44 |
| Female |
52 |
28 |
|
Location | ||
| Frontal | 26 | 18 |
| Temporal | 25 | 11 |
| Parietal | 31 | 12 |
| Occipital | 9 | 1 |
| >1 lobe |
41 |
30 |
|
Grade | ||
| II | 31 | |
| III | 20 | |
| IV |
81 |
72 |
|
Events | ||
| Death | 77 (Follow-up: 1–41 months, median 11 months) | 68 (Follow-up: 1–24 months, median 10 months) |
| Censored |
49 (Follow-up: 3–74 months, median 18 months) |
4 (Follow-up: 13–36, median 15.5 months) |
|
Surgery | ||
| Partial | 74 | 3 |
| Complete | 48 | 68 |
| NA |
10 |
1 |
|
Radiotherapy | ||
| Yesa | 95 | 53 |
| No | 17 | 3 |
| NA |
20 |
16 |
|
Chemotherapy (temozolomide) | ||
| Yes | 39 | 54 |
| No | 14 | 0 |
| NA | 79 | 18 |
a
Postoperative radiotherapy (a total dose of 60 Gy in 30–33 fractions).